CeriBell (CBLL) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 thank you for standing by. At this time, I would like to welcome you to the Cerebell Q1 twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Elizabeth Spariccio, Investor Relations. Please go ahead. Speaker1 Good afternoon, and thank you all for participating in today' ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-42364 CeriBell, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-1785452 | ...

Ceribell Reports First Quarter 2025 Financial Results SUNNYVALE, Calif., May 8, 2025 – CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Cash, cash equivalents, and marketable securities totaled $182.7 million as of March 31, 2025. 2025 Financial Outlook Ceribell is raising i ...

SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achi ...

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time. Event ...

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company transforming the diagnosis and management of p ...

SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025. Investors i ...

Ceribell, Inc. (CBLL) recently announced that it has received FDA clearance for the Clarity algorithm for use in pediatric patients. This breakthrough expands the utility of Ceribell’s rapid electroencephalography (“EEG”) system, enabling faster seizure detection and treatment in critically ill children.With this clearance, Ceribell strengthens its position in the neurodiagnostic space by addressing a critical gap in pediatric care. The Clarity algorithm is designed to support timely clinical decisions, imp ...

References Forward-Looking Statements SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1 and older. This makes Ceribell the ...

Core Insights - Ceribell, Inc. has received FDA 510(k) clearance for its Ceribell Clarity™ algorithm, making it the first AI-powered point-of-care EEG system capable of detecting electrographic seizures in patients aged 1 and older [1][2][3] - The Clarity algorithm is designed to provide comprehensive seizure detection across the largest age range ever addressed by such technology, enhancing the capabilities of hospitals, particularly in emergency departments and ICUs [1][3] - The pediatric clearance was supported by EEG data from over 1,700 patients, marking it as the largest validation dataset for FDA clearance of a seizure detection system [1][3] Company Overview - Ceribell is a medical technology company focused on improving the diagnosis and management of serious neurological conditions through its innovative EEG platform [6] - The Ceribell System combines portable hardware with AI-powered algorithms to enable rapid diagnosis and continuous monitoring of neurological conditions, currently utilized in intensive care units and emergency rooms across the U.S. [6] Industry Impact - The FDA clearance is expected to significantly impact the lives of critically ill children, who are at high risk for preventable brain injury due to seizures [3] - Non-convulsive seizures, which can only be detected through EEG, require prompt identification and treatment to prevent brain injury, highlighting the importance of rapid EEG access [3]